Austin Texas based Maxwell Biosciences is raising $14,822,750.00 in New Equity Investment.
Austin, TX – According to filings with the U.S. Securities and Exchange Commission, Maxwell Biosciences is raising $14,822,750.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Joshua Mcclure played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Maxwell Biosciences
Founded in 2016, Maxwell is a preclinical stage biotech targeting viral pandemics. Stanford and NYU scientists invented a new class of broad spectrum anti-infective therapeutics that attack the virus structure directly. Maxwell develops biostable, low molecular weight compounds which are functional mimics of peptides (peptidomimetics) at roughly one-quarter the size, and are distinct from macromolecules due to their ability to easily penetrate membranes. Our core mission is to create health for the world safely and affordably. Maxwells CLAROMER brand anti-infectives platform outputs a diverse library of oligomeric structures demonstrated to be well tolerated in animals and to potently disrupt the membranes of a broad spectrum of viruses and other pathogens, as shown in preclinical animal studies and electron micrograph imaging of bacterial, viral and fungal structures after CLAROMER treatment. They have also been shown in preclinical studies to be well tolerated in human tissues in vitro and in vivo in animal studies. Maxwells technology is protected by granted patents.
To learn more about Maxwell Biosciences, visit http://maxwellbiosciences.com/
Contact:
Joshua Mcclure, President and Chief Executive Officer
855-629-2461
joshua@maxwellbiosciences.com
https://www.linkedin.com/in/joshuamcclure/
SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved